Literature DB >> 32938720

Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.

Sonia J Parikh1, Chiara M Evans1, Juliet O Obi1, Qinghai Zhang1, Keiko Maekawa1, Karen C Glass1, Manish B Shah2.   

Abstract

The human CYP2C9 plays a crucial role in the metabolic clearance of a wide range of clinical therapeutics. The *2 allele is a prevalent genetic variation in CYP2C9 that is found in various populations. A marked reduction of catalytic activity toward many important drug substrates has been demonstrated by CYP2C9*2, which represents an amino acid variation at position 144 from arginine to cysteine. The crystal structure of CYP2C9*2 in complex with an antihypertensive drug losartan was solved using X-ray crystallography at 3.1-Å resolution. The Arg144Cys variation in the *2 complex disrupts the hydrogen-bonding interactions that were observed between the side chain of arginine and neighboring residues in the losartan complex of CYP2C9 and the wild-type (WT) ligand-free structure. The conformation of several secondary structural elements is affected, thereby altering the binding and orientation of drug and important amino acid side chains in the distal active site cavity. The new structure revealed distinct interactions of losartan in the compact active site of CYP2C9*2 and differed in occupancy at the other binding sites previously identified in the WT-losartan complex. Furthermore, the binding studies in solution using losartan illustrated lower activity of the CYP2C9*2 compared with the WT. Together, the findings yield valuable insights into the decreased hydroxylation activity of losartan in patients carrying CYP2C9*2 allele and provide a useful framework to investigate the effect of a single-nucleotide polymorphism that leads to altered metabolism of diverse drug substrates. SIGNIFICANCE STATEMENT: The *2 allele of the human drug-metabolizing enzyme CYP2C9 is found in different populations and results in significantly reduced activity toward various drug substrates. How the CYP2C9*2 variant induces altered drug metabolism is poorly understood given that the Arg144Cys variation is located far away from the active site. This work yield insight into the effect of distal variation using multitude of techniques that include X-ray crystallography, isothermal titration calorimetry, enzymatic characterization, and computational studies.
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32938720      PMCID: PMC7569312          DOI: 10.1124/molpharm.120.000042

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  44 in total

1.  Integration of macromolecular diffraction data.

Authors:  A G Leslie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-10

2.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

3.  Analysis of void volumes in proteins and application to stability of the p53 tumour suppressor protein.

Authors:  Alison L Cuff; Andrew C R Martin
Journal:  J Mol Biol       Date:  2004-12-10       Impact factor: 5.469

Review 4.  Cytochrome P450 2C9-CYP2C9.

Authors:  Derek Van Booven; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

Review 5.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

6.  Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Authors:  Pamela A Williams; Jose Cosme; Alison Ward; Hayley C Angove; Dijana Matak Vinković; Harren Jhoti
Journal:  Nature       Date:  2003-07-13       Impact factor: 49.962

7.  Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Methods Mol Biol       Date:  2013

8.  Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine.

Authors:  J Nourooz-Zadeh; J Tajaddini-Sarmadi; S P Wolff
Journal:  Anal Biochem       Date:  1994-08-01       Impact factor: 3.365

9.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

10.  BALBES: a molecular-replacement pipeline.

Authors:  Fei Long; Alexei A Vagin; Paul Young; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more
  2 in total

1.  Insights into the Genetic Variations of Human Cytochrome P450 2C9: Structural Analysis, Characterization and Comparison.

Authors:  Sonia J Parikh; Sumit Kamat; Margaret Phillips; Samuel P Boyson; Thomas Yarbrough; Dylan Davie; Qinghai Zhang; Karen C Glass; Manish B Shah
Journal:  Int J Mol Sci       Date:  2021-09-22       Impact factor: 5.923

Review 2.  Inhibition of CYP2C8 by Acyl Glucuronides of Gemfibrozil and Clopidogrel: Pharmacological Significance, Progress and Challenges.

Authors:  Manish B Shah
Journal:  Biomolecules       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.